Aditxt (NASDAQ:ADTX – Get Free Report) and Merck & Co., Inc. (NYSE:MRK – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.
Profitability
This table compares Aditxt and Merck & Co., Inc.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
| Merck & Co., Inc. | 4.77% | 16.73% | 6.13% |
Volatility and Risk
Aditxt has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Merck & Co., Inc. | 0 | 7 | 17 | 0 | 2.71 |
Merck & Co., Inc. has a consensus target price of $154.24, suggesting a potential upside of 3.69%. Given Merck & Co., Inc.’s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Aditxt.
Institutional & Insider Ownership
15.5% of Aditxt shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 0.0% of Aditxt shares are held by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Aditxt and Merck & Co., Inc.”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $14,336.00 | 0.26 | -$41.71 million | ($100,788.35) | -0.00 |
| Merck & Co., Inc. | $65.01 billion | 5.65 | $18.25 billion | $1.25 | 119.00 |
Merck & Co., Inc. has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.
Summary
Merck & Co., Inc. beats Aditxt on 13 of the 14 factors compared between the two stocks.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
About Merck & Co., Inc.
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
